Generation and characterization of a JAK2V617F-containing erythroleukemia cell line.
The JAK2V617F mutation is found in the majority of patients with myeloproliferative neoplasms (MPNs). Transgenic expression of the mutant gene causes MPN-like phenotypes in mice. We have produced JAK2V617F mice with p53 null background. Some of these mice developed acute erythroleukemia. From one of...
Main Authors: | Wanke Zhao, Kang Zou, Taleah Farasyn, Wanting Tina Ho, Zhizhuang Joe Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4103785?pdf=render |
Similar Items
-
JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines
by: Zhao Wanke, et al.
Published: (2012-06-01) -
Development of a highly sensitive method for detection of JAK2V617F
by: Gao Rufei, et al.
Published: (2011-10-01) -
Relevance of JAK2V617F positivity to hematological diseases - survey of samples from a clinical genetics laboratory
by: Ho Wanting T, et al.
Published: (2011-01-01) -
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.
by: Jerry L Spivak, et al.
Published: (2020-01-01) -
The Jak2 Inhibitor, G6, Alleviates Jak2-V617F–Mediated Myeloproliferative Neoplasia by Providing Significant Therapeutic Efficacy to the Bone Marrow
by: Annet Kirabo, et al.
Published: (2011-11-01)